GlassScriptPhysician profile
Sanjay Logani
NPI 1124131958
$9,215.22
in general payments reported to CMS, 2019-2025
30 companies · $1,042 in 2025
The $1,042 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,590 · 2020: $1,072 · 2021: $863 · 2022: $672 · 2023: $2,662 · 2024: $1,314 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,182 · Debt Forgiveness: $1,817 · Entertainment: $18.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,181.99 |
| Debt Forgiveness | $1,816.85 |
| Entertainment | $18.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $1,816.85 | 2023 | |
| Novartis Pharmaceuticals Corporation | $853.33 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $789.19 | 2019-2025 | Eylea Hd, Eylea |
| Sun Pharmaceutical Industries INC. | $700.51 | 2019-2025 | Cequa |
| Alcon Vision LLC | $648.55 | 2019-2025 | Clareon, Tryptyr, Eysuvis |
| Glaukos Corporation | $523.63 | 2019-2021 | |
| Allergan, INC. | $516.30 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $430.18 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Amgen INC. | $417.56 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $409.66 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $315.59 | 2019-2020 | |
| Dompe US, INC. | $244.07 | 2022-2025 | Oxervate |
| Harrow Eye, LLC | $222.98 | 2024-2025 | Vevye, Iheezo, Tobradex St |
| Oyster Point Pharma, INC. | $210.32 | 2022-2025 | Tyrvaya |
| Sight Sciences, INC. | $148.81 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $135.69 | 2019-2023 | Iluvien |
| Eyepoint US, INC. | $125.00 | 2021 | |
| Biotissue Holdings INC. | $124.56 | 2019-2022 | |
| Genentech USA, INC. | $103.22 | 2022-2023 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $100.84 | 2025 | Xdemvy |
| Quidel Corporation | $91.65 | 2019 | |
| Horizon Therapeutics Plc | $61.15 | 2023 | Tepezza |
| Shire North American Group INC | $47.06 | 2019 | |
| Beaver-Visitec International, INC. | $43.10 | 2021 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Eyevance Pharmaceuticals LLC | $26.97 | 2020 | |
| Optos, INC. | $18.88 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Abbvie INC. | $18.53 | 2024 | |
| Kala Pharmaceuticals, INC. | $17.90 | 2022 | |
| Vyera Pharmaceuticals, LLC | $14.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Logani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.